Business Context and Reporting Period
This Form 8-K Current Report, filed on July 25, 2025, by UnitedHealth Group Incorporated (UNH), discloses a significant executive leadership change. The report details the appointment of a new Chief Financial Officer (CFO) and the transition of the incumbent CFO to a strategic advisory role.
Key Financial Metrics
This filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the departure of John F. Rex as CFO and the appointment of Wayne S. DeVeydt as the new CFO, effective September 2, 2025.
- Outgoing CFO: John F. Rex, who served as CFO since 2016, will transition to the role of Strategic Advisor to the CEO.
- Incoming CFO: Wayne S. DeVeydt, currently a Managing Director at Bain Capital and former CFO of Elevance Health (Anthem), will assume the role.
Management Commentary and Compensation Terms
The filing outlines the specific compensatory arrangements for Mr. DeVeydt under his new employment agreement:
- Base Salary: $1,000,000 annually.
- Annual Bonus: Target of 200% of base salary ($2,000,000).
- Sign-on Bonus: $1,200,000 cash, subject to clawback provisions.
- Sign-on Stock Award: $5,000,000 fair value (split between RSUs and NSOs).
- Annual Stock Award Target: $10,000,000 fair value. The pro-rated 2025 award is $3,000,000, consisting of $1.5M in RSUs/NSOs and $1.5M in Performance-Based RSUs (PSUs).
- Severance: Eligible for two times base salary plus the sum of the last two years' annual bonuses upon termination without "cause" or resignation for "good reason."
- Vesting: RSUs and NSOs vest ratably over four years; PSUs cliff vest over three years.
Investor Verification Checklist
- Verify the effective date of the CFO transition (September 2, 2025) and the interim financial reporting responsibilities.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason" regarding severance and clawbacks.
- Assess the impact of the $10M annual stock award target on future equity dilution and compensation expense.
- Confirm the strategic rationale for the leadership change as detailed in the accompanying press release (Exhibit 99.1).